Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 13

1195P - Neuroendocrine Tumors (NETs): How Big Data (BD) techniques applied to Electronic Health Records (EHR) can improve our understanding of this patient population

Date

21 Oct 2023

Session

Poster session 13

Topics

Population Risk Factor;  Rare Cancers

Tumour Site

Neuroendocrine Neoplasms

Presenters

Jorge Hernando

Citation

Annals of Oncology (2023) 34 (suppl_2): S701-S710. 10.1016/S0923-7534(23)01264-4

Authors

J. Hernando1, J. Fuster Salva2, J.A. Balsa3, D. Malon Gimenez4, A. Grandoulier5, C. Courteval6, J. Valdivieso7, J.J. Díez Gómez8

Author affiliations

  • 1 Medical Oncology Department, Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), 8035 - Barcelona/ES
  • 2 Medical Oncology, Hospital Universitario Son Espases, 07120 - Palma de Mallorca/ES
  • 3 Endocrinology, Infanta Sofía University Hospital, 28702 - San Sebastián de los Reyes/ES
  • 4 Medical Oncology Department, Hospital Universitario de Fuenlabrada, 28942 - Fuenlabrada/ES
  • 5 Biostatistician, IPSEN Pharma, 75016 - Boulogne/FR
  • 6 Medical Advisor, IPSEN S.A., Barcelona/ES
  • 7 Biostatistics, MEDSAVANA S.L., 28004 - Madrid/ES
  • 8 Endocrinology, University Hospital Puerta de Hierro Majadahonda, 28222 - Majadahonda/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1195P

Background

Low incidence and heterogeneity of NETs complicates the study of epidemiological and clinical pathways in this population. There is an unmet need for large datasets and BD tools to fill this knowledge gap. Our study aimed to describe the demographic and clinical characteristics of patients with NETs in Spain through the application of BD techniques to EHR.

Methods

This was a retrospective, observational study in adult patients with NETs managed in 5 Spanish centers between 01/01/2014 to 31/12/2019. An unstructured search of free text from EHRs was performed by artificial intelligence (AI) techniques based on SAVANA’s EHRead®, an innovative Natural Language Processing and machine learning system. Patients were included when NET was first identified (Index Date) and classified as `Incident´ or `Prevalent´ if the Index Date was within the study window or not, respectively.

Results

A total of 2,939,309 patients were screened by EHRead and 1,256 NETs cases were found: median age 60y (95% CI 59 - 62), 52% female, 41% with gastroenteropancreatic origin, and 44% were categorized as incident (Table). More than 70% of patients presented symptoms prior to diagnosis and >10% had metastases at diagnosis (>70% were non-resectable). Median time from symptom onset to first diagnosis was 0.6 years (95% CI 0.4 - 0.73). The most frequently detected comorbidities were hypertension (66%), diabetes (35%), asthma (22%), and depression (17%). A previous diagnosis of cancer different from NETs was reported in 21% of cases. Uncommon clinical events included brain metastases (1%) and familial history of NETs (1.1%). Table: 1195P

Classification of patients with NETs

FAS (N=1,256) n (%) Prevalent (N=700) n (%) Incident (N=556) n (%)
Patients with symptoms before Index Date 366 (29.1) 0 (0) 366 (65.8)
Primary NET site
Gastroenteropancreatic 412 (41.4) 235 (42.7) 177 (39.7)
Bronchopulmonary 171 (17.2) 81 (14.7) 90 (20.2)
Other* 413 (41.5) 234 (42.5) 179 (40.1)
Classified by surgery at Index Date§
Thyroidectomy 9 (0.9) 3 (0.5) 6 (1.3)
Adrenalectomy 1 (0.1) 0 (0) 1 (0.2)
Other classifications 1 (0.1) 1 (0.2) 0 (0)
Unclassified NETs 260 (20.7) 150 (21.4) 110 (19.8)

* Paraganglioma, adrenal gland and medullary thyroid carcinomas and pheochromocytomas§ Within +/-6 months of Index Date

Conclusions

BD Techniques should improve generation of large datasets in low incidence neoplasms and help identify uncommon events. NETs diagnosis is delayed about 6m after symptom onset and comorbidities may influence the choice of treatment.

Clinical trial identification

Editorial acknowledgement

Editorial assistance was provided by Content Ed Net (Madrid, Spain)

Legal entity responsible for the study

IPSEN Pharma.

Funding

IPSEN Pharma.

Disclosure

J. Hernando: Financial Interests, Personal, Advisory Board: Eisai, Ipsen, Novartis, AAA, Angelini, Pfizer, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.